Akcea gibt Zulassung der Kostenübernahme für TEGSEDI® (Inotersen) in Spanien zur Behandlung von hereditärer Transthyretin-vermittelten Amyloidose mit Polyneuropathie bekannt

Disclaimer: The views, suggestions and opinions expressed here are the sole responsibility of the experts. No ZEX PR Wire journalist or Editor was involved in the writing and production of this article. TEGSEDI ist das erste Antisense-Arzneimittel, das sich Patienten in Spanien als subkutane Injektion zu Hause selbst verabreichen können Read more

May 16, 2020|

Dungeon Forward Presents Couch A Vibe Festival

Disclaimer: The views, suggestions and opinions expressed here are the sole responsibility of the experts. No ZEX PR Wire journalist or Editor was involved in the writing and production of this article. Press Release - updated: May 16, 2020 08:00 EDT MIAMI, May 16, 2020 (Newswire.com) - Although the world Read more

May 16, 2020|
Go to Top